YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Immunic appoints Chitrang Davé as chief data and digital officer Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it has appointed Chitrang Davé as chief data and digital officer, effective…
Immunic advances MS drug toward key Phase 3 data, expects results by year-end Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances…
Immunic appoints Elena Ridloff to board of directors Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff curr…
Immunic Inc (NASDAQ:IMUX, FRA:10VA) CEO Erik Lundgren spoke with Proactive's Stephen Gunnion about the company's second-quarter results, its leadership transition and the milestones set to shape the next phase of its multiple sclerosis (MS…
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief executive officer as the company advances its multiple sclerosis treatment candidate through late-stage development and prepares for poten…
Immunic, Inc(NASDAQ:IMUX) announced it strengthened its leadership team on Wednesday as the company prepares to advance its multiple sclerosis pipeline through late-stage development and potential commercialization. Immunic Appoints Erik L…
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings mor…
4:20pm: S&P 500 retreats for third straight session Stocks closed lower for a third straight session on Tuesday as rising Treasury yields and lingering inflation concerns continued to pressure equities, pulling the major indexes further aw…
– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK, May 19, 2026 /PRNewswire/ -- Immunic, Inc. (Nas…
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line Phase 3 data for its lead multiple sclerosis drug candidate, vidofludimus calcium, by the end of 2026, as the company strengthens its leadership…
4:20pm: Another record day Stocks finished mixed on Wednesday, but the mood on Wall Street remained broadly upbeat as another rally in technology shares pushed the S&P 500 and Nasdaq Composite to fresh record highs despite hotter-than-expe…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
Immunic to implement 1-for-10 reverse stock split Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced it will implement a 1-for-10 reverse stock split of its common shares, effective April 27, as p…
NEW YORK, April 23, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or "Immunic"), today announced that it will…
* Immunic (IMUX [https://seekingalpha.com/symbol/IMUX]) on Wednesday said it has received written notice from Nasdaq, informing that it has regained compliance with the minimum bid price requirement as the closing bid price of the company'…
NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Noti…
Immunic appoints biopharmaceutical executive Jon Congleton to board Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to i…
– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis – – Served on Original Team Responsible for the Launch of Copaxone® in the United States – NEW YORK, March 31, 2026 /P…
The S&P 500(SNPINDEX:^GSPC) fell 0.37% to 6,556.37, and the Nasdaq Composite(NASDAQINDEX:^IXIC) dropped 0.84% to 21,761.89 on tech and software weakness. The Dow Jones Industrial Average(DJINDICES:^DJI) slipped 0.18% to 46,124.06 after a d…
Immunic, Inc. (NASDAQ:IMUX) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 10, 2026, Immunic, Inc. (NASDAQ:IMUX) announced that the European Patent Office granted a key patent covering label-relevant dosing regimens fo…
Immunic secures $400M to support late-stage MS trials - ICYMI Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support c…
Immunic sets stage for phase 3 MS data readout after $400M financing Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX) said it is entering a pivotal period for its multiple sclerosis program after securing up to $40…
Immunic closes $200M private placement to fund late-stage MS trials Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 mi…
[Green arrow pointing up and a dollar sign] Fabricio Rosa/iStock via Getty Images Immunic (IMUX [https://seekingalpha.com/symbol/IMUX]) shares climbed ~26% in the premarket on Friday after the immunology drug developer announced a private…
(RTTNews) - Immunic, Inc. (IMUX) has announced an oversubscribed private placement of up to $400 million, a financing designed to support the company's transition from a late-stage R&D organization into a fully integrated commercial-stage…
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progres…
Immunic, Inc. (NASDAQ:IMUX) is one of the stocks under $1 that will explode.Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% An array of pharmaceutical pills with the company's logo on the bottle…
* Immunic press release [https://seekingalpha.com/pr/20305667-immunic-inc-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (IMUX [https://seekingalpha.com/symbol/IMUX]): Q3 GAAP EPS of -$0.13 beats by $0.06. * Ca…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: KeyBanc upgraded Datadog (DDOG) to Overweigh…
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan C…
Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company with a market capitalization of approximately $80 million, announced that on Monday its board of directors authorized grants of up to 35,000,000 stock appreciation rig…
NEW YORK - Immunic, Inc. (NASDAQ:IMUX) announced Tuesday that 92.3% of patients treated with its experimental multiple sclerosis drug vidofludimus calcium remained free of 12-week confirmed disability worsening after 144 weeks of treatment…
Daniel Vitt, the CEO and Director of $IMUX, bought 15,000 shares of the company on 06-04-2025 for an estimated $11,550. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of th…
– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis – – Positive Results From Phase 1b Clinical Trial o…
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced…
In this article, we will take a look at the 10 best rated penny stocks to buy according to analysts. To see more such companies, go directly to 5 Best Rated Penny Stocks to Buy According to Analysts. Investing in small companies, penny sto…